Intervention not reported
Social confidence, social inclusion, social networks or personalised quality of life measures ‐ no clinically significant change · people with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Pre‐eclampsia · pregnant women
The intervention may leads to lower pre‐eclampsia (low certainty).
1 finding from 1 review
Intervention not reported
Preterm birth · pregnant women
The intervention may leads to lower preterm birth (low certainty).
1 finding from 1 review
Intervention not reported
HELLP syndrome · pregnant women
The intervention leads to higher HELLP syndrome (high certainty).
1 finding from 1 review
Intervention not reported
Number of attacks · primary Raynaud's phenomenon
1 finding from 1 review
Intervention not reported
Duration of attacks · primary Raynaud's phenomenon
1 finding from 1 review
Intervention not reported
Severity scores · primary Raynaud's phenomenon
1 finding from 1 review
Intervention not reported
Patient preference scores · primary Raynaud's phenomenon
1 finding from 1 review
Intervention not reported
Exercise capacity · patients with pulmonary hypertension secondary to systemic scleroderma.
1 finding from 1 review
no estimate extracted
67 participants
Very low
Intervention not reported
WHO/NYHA functional class · patients with pulmonary hypertension secondary to systemic scleroderma.
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
50% or greater reduction in seizure frequency Number of seizures · patients with drug‐resistant epilepsy
Flunarizine showed no clear difference in 50% or greater reduction in seizure frequency Number of seizures compared with placebo (high certainty).
1 finding from 1 review
Treatment withdrawal · patients with drug‐resistant epilepsy
Flunarizine probably leads to higher treatment withdrawal Number of withdrawals compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects ‐ Blurred vision No of patients with blurred vision · patients with drug‐resistant epilepsy
Flunarizine showed no clear difference in adverse effects ‐ Blurred vision No of patients with blurred vision compared with placebo (high certainty).
1 finding from 1 review
Frequency of adverse effects ‐ dizziness ( · patients with drug‐resistant epilepsy
Flunarizine showed no clear difference in adverse effects ‐ Dizziness No of patients with dizziness compared with placebo (high certainty).
1 finding from 1 review
Adverse effect: fatigue · patients with drug‐resistant epilepsy
Flunarizine showed no clear difference in adverse effects ‐ Fatigue No of patients with fatigue compared with placebo (high certainty).
1 finding from 1 review
Irritability · patients with drug‐resistant epilepsy
Flunarizine showed no clear difference in adverse effects ‐ Irritability No of patients with irritability compared with placebo (high certainty).
1 finding from 1 review
Adverse events: Vomiting · patients with drug‐resistant epilepsy
Flunarizine showed no clear difference in adverse effects ‐ Vomiting No of patients with vomiting compared with placebo (high certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency Number of seizures · patients with drug‐resistant epilepsy
Nimodipine showed no clear difference in 50% or greater reduction in seizure frequency Number of seizures compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawal · patients with drug‐resistant epilepsy
Nimodipine showed no clear difference in treatment withdrawal Number of withdrawals compared with placebo (moderate certainty).
1 finding from 1 review